Pulmonary embolism is a clinical and pathological syndrome of pulmonary cycling disorders caused by internal or external embolism, which usually requires anticondensation treatment. However, for specific groups, such as pregnant women, children, the elderly and patients with haemorrhagic tendencies or a combination of other diseases, anticondensation treatment needs to be more cautious, with the following strategies:
I. Pregnant women
1. Drug choice: Pregnant women need to weigh mother-child safety in anticondensation treatment. Low molecular heparin is usually preferred, as it does not pass through the placenta and has a lesser impact on the foetus. Avoiding the use of drugs such as Wafarin that may have a teratogenic effect on the foetus.
2. Dose adjustment: The dose of low molecular heparin is adjusted to the weight and coagulation function of the pregnant woman to ensure anticondensation while reducing hemorrhage risk.
3. Monitoring and follow-up: periodic monitoring of the coagulation function of pregnant women, foetal condition and maternal complications, such as haemorrhage, haemorrhage formation, etc.
II. CHILDREN
1. Drug choice: The anticondensation treatment of pulmonary embolism in children requires the choice of drugs according to age, weight and condition. Low molecular heparin is a commonly used anticondenser, subject to a dose adjustment based on the weight of the child.
2. Monitoring and adjustment: closely monitoring indicators such as the coagulation function of children, slab count, and timely adjustment of the dose of anticondensatives to avoid haemorrhage or leeching. At the same time, attention is paid to the potential impact of drugs on the growth and development of children.
III. Older persons
1. Drug choice: Older persons often combine multiple diseases such as hypertension, diabetes, etc., with the choice of anticondensants that have less impact on liver and kidney functions, such as low molecular hepatogens or new oral anticondensants.
2. Dose adjustment: The dose of anticondensed drugs is adjusted to the liver and kidney function, coagulation function and condensation of the elderly to ensure safety and effectiveness. Avoiding the adverse effects of excessive internal accumulation of drugs.
3. Be aware of the risk of haemorrhage: the risk of haemorrhage, such as haemorrhage in digestive tracts, brain haemorrhage, etc., needs special attention in anticondensation treatment for older persons, and indicators such as coagulation function and blood protocol are regularly monitored.
IV. Patients with a tendency to haemorrhage or to combine other diseases
1. Risk assessment: In cases of haemorrhagic tendencies or combinations of other diseases (e.g., digestive ulcer, severe liver and kidney diseases, etc.), the advantages and disadvantages of anticondensation treatment must be assessed, and the risk of haemorrhage is weighed against the risk of haemorrhagic leoparding.
2. Drug selection: Based on the patient ‘ s specific circumstances, anticondensants with a lower risk of haemorrhage, such as low molecular hepatin or new oral anticondensants, are selected.
3. Monitoring and adjustment: closely monitoring of the patient ‘ s coagulation function, blood routines, etc., and timely adjustment of the dose of anticondensatives or detoxification to avoid haemorrhage or haemorrhage formation.
V. Attention to anticondensation treatment
1. Patient education: explain in detail to the patient and his/her family the purpose, methods and care of anti-condensation treatment, and improve the patient ‘ s ability to comply with treatment and self-management.
2. Regular drug use: The patient is required to take the drug in accordance with the doctor ‘ s instructions and to avoid leaking or self-deactivation.
3. Dietary adjustment: a nutritionally balanced diet, with more protein- and vitamin-rich food, and avoiding over-oiled, high cholesterol.
4. Motivation: Appropriate sport, such as walking, jogging, etc., can help to promote blood circulation and reduce the risk of haematation, depending on the patient ‘ s circumstances.
5. Regular follow-up visits: regular follow-up visits to hospitals to assess the medical condition and the effectiveness of anticondensation treatment, and timely adjustment of treatment programmes.
In short, for pulmonary embolism and condensation treatments for specific groups of people, individualized treatments need to be tailored to the specific circumstances of the patient to evaluate the advantages and disadvantages and ensure safety and effectiveness. At the same time, patients are required to actively cooperate with the doctor ‘ s recommendations for treatment and to conduct regular follow-up and management.
